Alan Mendelson is the Corporate Counsel for Whole Biome and is a Partner at Latham & Watkins where he represents emerging and public growth companies, primarily in the life sciences industry. He served as the Co-chair of the firm’s Emerging Companies Practice from 2001 to 2013 and currently is Co-chair of the Life Sciences Industry Group. Alan has handled and supervised a variety of major business transactions.

Alan currently serves on the Board of Directors of the California Life Sciences Association (CLSA), the Board of Trustees of the UC Berkeley Foundation and the Board of Advisors for the UC Berkeley Department of Chemistry. Alan previously served on the Board of Directors of the Biotechnology Industry Organization (BIO), the Board of Trustees of The Scripps Research Institute and the BayBio Board of Directors. He serves as the corporate secretary for many public and private companies. Alan is a member of the UC Innovation Council to advise UC President Janet Napolitano on technology and entrepreneurship initiatives for the UC system. From 2009 to 2011, Alan served as President of the Cal Alumni Association. Previously, Alan served as the President of the National Kidney Foundation of Northern California, Inc., as a member of the Board of Regents of the University of California and as a member of the Board of Overseers Visiting Committee of Harvard Law School.

Alan serves as a member of the Major Gifts Council for the Lucile Packard Foundation for Children’s Health and as a member of the Board of the American Friends of Rambam Medical Center, Haifa, Israel. Alan received his AB from the University of California, Berkeley and his J.D. from Harvard Law School.


Vern Norviel has been the Intellectual Property Counsel for Whole Biome since 2013 and sets the strategic direction for the patent portfolio. Vern is a Partner at Wilson Sonsini Goodrich & Rosati, where he leads the patents and innovation counseling practice. Vern has three decades of experience in formulating successful strategies for life science companies and the development of their IP programs. He represents a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. In fact, Vern’s interest in the field of personalized medicine prompted him to become the first attorney to have had his or her entire genome sequenced and made available in a public database.
Before joining the firm in 2003, Vern was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He also had been a partner at Townsend and Townsend and Crew in Palo Alto.
Vern currently serves as a member of Wilson Sonsini Goodrich & Rosati’s Executive Committee and on the board of the WSGR Foundation. In addition, he is a lecturer in biotechnology law at UC Berkeley School of Law. Vern received his B.A. from the University of Colorado, Boulder, his Masteres from the University of Santa Clara and his J.D. from the University of San Francisco School of Law.